Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunopathology and Immunotherapy for Breast Cancer Publisher



Ghaffari N1, 2 ; Razi S2, 3, 4 ; Keshavarzfathi M2, 4, 5 ; Rezaei N6, 7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Breast Cancer Association (BrCA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  5. 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors Published:2020


Abstract

Breast cancer is the most common cancer-related cause of death among women worldwide. There are several therapeutic choices for its treatment, such as radiotherapy, chemotherapy, surgery, and hormone replacement therapy (HRT). Despite all the advancements in these approaches, the treatment of patients with breast cancer is still an issue. It has become evident that the immune system has a significant role in the prevention, progression, and treatment of cancer. Thus, improving its power to treat cancers is a fact that has led to the development of immune-based anticancer drugs. Immunotherapy has shown promising results in the treatment of patients with breast cancer. In this chapter, we review the role of the immune system in breast cancer and different methods of immunotherapy, including targeted therapy using monoclonal antibodies (mAb), vaccines, immune checkpoint inhibitors, and adoptive T-cell therapy for patients with breast cancer. © Springer Nature Switzerland AG 2020. All rights reserved.
Related Docs
View other Related Docs
1. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
2. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
3. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
4. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
5. Tumor Immunology, Clinical Immunology (2022)
6. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
7. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
8. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (30)
Hamid Reza Mirzaei (8)
Other Related Docs
9. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
10. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
11. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
12. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
13. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
14. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
15. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
16. Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines, Expert Review of Vaccines (2022)
17. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
18. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
19. Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer, BMC Complementary Medicine and Therapies (2022)
20. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
21. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
22. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
23. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
24. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review, Cancer Cell International (2023)
25. The Tale of Tils in Breast Cancer: A Report From the International Immuno-Oncology Biomarker Working Group, npj Breast Cancer (2021)
26. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
27. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-Ctla-4 and Doxil Combination Therapy, International Journal of Nanomedicine (2020)
28. Ctla-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer, Current Molecular Medicine (2023)
29. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
30. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
31. Role of Btla/Hvem Network in Development of Gastric Cancer, Human Immunology (2022)
32. Licensed Monoclonal Antibodies and Associated Challenges, Human Antibodies (2015)
33. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
34. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
35. Precision Medicine in Non Communicable Diseases, International Journal of Molecular and Cellular Medicine (2019)
36. Recent Progress in Topical and Transdermal Approaches for Melanoma Treatment, Drug Delivery and Translational Research (2025)
37. Crispr/Cas9-Mediated Tgfβrii Disruption Enhances Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T Cells in Vitro, Journal of Translational Medicine (2021)
38. Chimeric Antigen Receptor T-Cell Therapy for Breast Cancer, Future Oncology (2021)
39. Breast Cancer Immunotherapy: Current and Novel Approaches, International Immunopharmacology (2021)
40. Immune Checkpoint Inhibition in Covid-19: Risks and Benefits, Expert Opinion on Biological Therapy (2021)
41. Immunopet: Antibody-Based Pet Imaging in Solid Tumors, Frontiers in Medicine (2022)
42. Pancancer Analysis Identifies Prognostic High-Apobec1 Expression Level Implicated in Cancer In-Frame Insertions and Deletions, Carcinogenesis (2018)
43. A Review on Leukemia and Ipsc Technology: Application in Novel Treatment and Future, Current Stem Cell Research and Therapy (2018)
44. Evaluation of the Immune Checkpoint Factors in Idiopathic Membranous Nephropathy, Molecular and Cellular Probes (2023)
45. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
46. The Potential Role of Immunotherapy in Wilms’ Tumor: Opportunities and Challenges, Current Pharmaceutical Design (2023)
47. Pro-Tumorigenic Functions of Macrophages at the Primary, Invasive and Metastatic Tumor Site, Cancer Immunology# Immunotherapy (2020)
48. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
49. Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-Cells for Immunotherapy of Non-Small Cell Lung Cancer, European Journal of Pharmaceutical Sciences (2023)
50. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)